Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues near the C-terminus of human PSMA was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
PSMA (Prostate-specific membrane antigen, Glutamate carboxypeptidase 2) is a membrane peptidase expressed in the prostate, central and peripheral nervous system, kidney, and small intestine (1). PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. It is required in the intestine for the uptake of folate, and in the brain it modulates excitatory neurotransmission through the hydrolysis of the neuropeptide N-acetylaspartylglutamate, thereby releasing glutamate (2). In the central nervous system, it is responsible for the cleavage of N-acetyl- L-aspartyl-L-glutamate yielding free glutamate in the synaptic cleft, and is implicated in various pathologic conditions associated with glutamate excitotoxicity (1). PSMA also has abundant and restricted expression on the surface of prostate carcinomas and the neovasculature of most other solid tumors, making it a target for cancer immunotherapy (3).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
